96 results about "Gut barrier" patented technology

The present invention pertains to a composition for inducing a pattern of gut barrier maturation similar to that observed with breast-feeding and able to improve gut barrier maturation, e.g. during neonatal stress. In particular, the present invention relates to an infant formula containing a combination of specific ingredients designed to provide a synergistic effect all along gastrointestinal tract and barrier function.

The invention relates to a liquid nutrition comprising short chain fatty acyl chains and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and / or prevention of gut barrier related disorders.

The invention discloses lactobacillus reuteri capable of intervening in metabolic syndrome and application, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1145 screened by the invention can significantly improve the increase of serum total cholesterol content of metabolic syndrome mice caused by high fat diet. The weight rise of metabolic syndrome individuals is relieved, and the daily diet intake and the energy efficiency are remarkably reduced. Fasting blood glucose and insulin resistance index levels of metabolic syndrome individuals are significantly improved. The rise of Romboutsia in the intestinal tract caused by high fat diet is obviously relieved. The levels of anti-oxidative stress CAT and SOD in the liver are remarkably improved, serum lipopolysaccharide endotoxin is inhibited, and a colon barrier structure is maintained. The lactobacillus reuteri CCFM1145 disclosed by the invention can be used for preparing pharmaceutical compositions and fermented foods for relieving diseases such as metabolic syndrome, non-alcoholic fatty liver disease and diabetes mellitus and the like, and has a very wide application prospect.

The present invention relates to novel isolated strains of Bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (TER) of a Caco-2 cell monolayer after 10 h treatment to more than 120% of TER at treatment start, ii) inducing secretion of >200 pg / ml of IL-10, and / or iii) inducing an IL-10:IL-12 ratio>1 when co-incubated with human PBMC derived dendritic cells. The strains may have one, two or all three of these capabilities. The present invention relates to the use of these novel strains for the in prevention, alleviation of symptoms, and treatment of diseases or conditions with an underlying impaired intestinal barrier function and pro-inflammatory activation of the mucosa. More specifically, the present invention relates to se of an isolated strain according to the invention for the prevention, alleviation of symptoms, or treatment of intestinal inflammatory conditions such as IBD and IBS, liver diseases such as NAFLD, NASH, cirrhosis, and alcohol-related liver disease, metabolic disorders such as metabolic syndrome, insulin resistance, type 2 diabetes, obesity, cardiovascular atherosclerosis, autoimmune diseases, such as celiac disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis, and mental conditions such as major depressive disorders, a mood disorder, a cognitive chronic fatigue syndrome, and anxiety.

The invention belongs to the field of biological medicines, relates to application of polygonatum sibiricum polysaccharides in preparation of medicines for treating ulcerative colitis, and in particular relates to application of polygonatum sibiricum polysaccharides in preparation of medicines for inhibiting release of inflammatory factors, regulating flora imbalance and repairing intestinal mucosal barrier injury. By adjusting the activity of neutrophil Myeloperoxidase (MPO), generation of inflammatory factors IL-6 and TNF-alpha is reduced, expression of an anti-inflammatory factor IL-10 is increased, inflammatory expression is inhibited, colon inflammation is improved by improving intestinal barrier, and potential application of polygonatum sibiricum polysaccharides in treatment of ulcerative colitis is expected to be explored.

The invention discloses a bacterial powder composition for relieving inflammatory colitis as well as a preparation method and application thereof, lactobacillus paracasei JN-1 freeze-dried bacterial powder with strong gastrointestinal digestive system resistance and bile salt tolerance is adopted, dietary fibers and vitamins are matched, and the lactobacillus paracasei JN-1 bacterial powder composition is prepared. The lactobacillus paracasei JN-1 can increase the number of beneficial bacteria and reduce the number of pathogenic bacteria, so that the homeostasis of intestinal microbiota is recovered, and cascade reaction of inflammatory factors can be reduced; dietary fibers which can be fermented by bacteria to form short-chain fatty acids are also added, so that the effects of resisting inflammation and enhancing the intestinal barrier function are achieved; in addition, vitamins with the functions of resisting inflammation, resisting oxidation, enhancing intestinal barrier function, improving immunity and the like are also added, so that the attack and progress of IBD are further reduced.

The invention discloses lactobacillus rhamnosus capable of intervening in metabolic syndrome and an application, in particular to a strain capable of intervening in metabolic syndrome. The lactobacillus rhamnosus can be added into various healthy foods and health-care foods, and belongs to the technical field of microorganisms. The invention provides lactobacillus rhamnosus CCFM1146 as well as a composition, a fermented food, an application, a microbial agent and a microbial agent preparation method thereof. According to the lactobacillus rhamnosus CCFM1146, the metabolic syndrome caused by high-fat diet are remarkably improved; the blood glucose, glucose tolerance and insulin resistance index level of metabolic syndrome mice are remarkably improved; the abundance of microorganisms in intestinal tracts is remarkably improved, and a colon barrier structure is maintained; and the level of proinflammatory factor IL-6 in liver is remarkably improved. The lactobacillus rhamnosus CCFM1146 isused for preparing pharmaceutical compositions and the fermented food for relieving the metabolic syndrome, non-alcoholic fatty liver disease, diabetes and other diseases, and has a very wide application prospect.

The invention discloses a lactic acid bacteria formula for preventing acute and chronic alcoholic liver injury and application thereof. Lactobacillus plantarum KLDS1.0344 and lactobacillus acidophilusKLDS1.0901 have good gastrointestinal fluid tolerance simulating capacity, have certain adhesion capacity to HT-29 cells and have basic probiotic characteristics; the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent acute alcoholic liver injury; and the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent chronic alcoholic liver injury. Specifically, the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 have the functions of reducing the liver index, improving the intestinal barrier, improving the liver function, reducing the inflammation level in the liver, increasing the content of short-chain fatty acid in the intestinal tract, reducing protein expression of CYP2E1 in the liver and the like.

The invention relates to a liquid nutrition comprising short chain fatty acyl chains, polyunsaturated fatty acyl chains, vegetable oil and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and / or prevention of gut barrier related disorders.

The present disclosure is directed to methods for i) promoting gut regeneration, ii) promoting gut maturation and / or adaptation, iii) supporting gut barrier resistance and / or iv) protecting gut barrier function in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic batch-cultivation process, such as Lactobacillus rhamnosus GG (LGG). The present methods advantageously provide the gut-protection benefits of LGG soluble mediators without introducing live bacterial culture to individuals with impaired gut barrier function. In some embodiments, the pediatric subject has impaired gut barrier function and / or short bowel syndrome. The present disclosure in other embodiments, directed methods for reducing visceral pain in a pediatric subject comprising administering to the pediatric subject a composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic batch-cultivation process, such as LGG.

The invention discloses lactobacillus reuteri CCFM1178 capable of intervening in metabolic syndrome, and application, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1178 screened by the invention can obviously eliminate increase of the serum total cholesterol content and the low-density lipoprotein cholesterol of a mouse with the metabolic syndrome caused by high fat diet, relieve the increase of the body weight of an individual with the metabolic syndrome, and reduce daily diet intake and energy conversion efficiency; the intestinal flora imbalance of the mouse due to high fat is eliminated; and the levels of proinflammatory factors IL-6 and TNF-[alpha] in the liver of the mouse with the metabolic syndrome are improved, and the level of an anti-inflammatory factor IL-10 is improved to prevent the metabolic syndrome, inhibit serum lipopolysaccharide endotoxin and maintain a colon barrier structure. The lactobacillus reuteri CCFM1178 disclosed by the invention can be used for preparing medicines or functional foods for relieving diseases such as the metabolic syndrome, the non-alcoholic fatty liver disease, the diabetes mellitus and the like, and has a very wide application prospect.

A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and / or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and / or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and / or obesity; an enteropathogenic infection; impaired gut barrier function and / or; an inflammation related to gastro intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

The invention discloses a probiotic strain for improving intestinal barrier function and application thereof, and relates to the field of probiotics. The probiotic strains provided by the invention are lactobacillus plantarum, pediococcus acidilactici, enterococcus faecium and escherichia coli; wherein the microbial preservation number of the lactobacillus plantarum is CGMCC No.17941; the microbial preservation number of the pediococcus acidilactici is CGMCC No.17943; the microbial preservation number of the enterococcus faecium is CGMCC No.17944; and the microbial preservation number of the escherichia coli is CGMCC No.17945. The probiotic strain provided by the invention can significantly inhibit the increase of intestinal permeability caused by intestinal barrier function damage and recover the intestinal permeability to a healthy level; can effectively relieve colitis and systemic inflammation symptoms caused by intestinal barrier function damage; in addition, the probiotic strain also has the effects of delaying senescence and prolonging the service life. The probiotic strain can be widely applied to products such as drugs for improving intestinal barrier function damage and related development diseases and delaying senescence, and the market application value is high.

The invention discloses bifidobacterium longum for relieving ulcerative colitis and application of the bifidobacterium longum, and belongs to the technical field of microorganisms. The Bifidobacterium longum NSP001 disclosed by the invention can stimulate human colon cancer cells Caco-2 to secrete superoxide dismutase, and can improve weight loss and DAI indexes of mice with ulcerative colitis, relieve damage to intestinal barriers and tissue structures, regulate secretion of inflammatory factors and oxidative stress level under the conditions of mouse and human intestinal florae, and can be used for preparing the superoxide dismutase for treating the ulcerative colitis and preventing and treating the ulcerative colitis, so that the bifidobacterium longum NSP001 can be used for preparing the superoxide dismutase for treating the ulcerative colitis. The production of intestinal short-chain fatty acid is promoted, the flora function is improved, and the intestinal health is recovered. In addition, the bifidobacterium longum can further prevent or relieve body metabolic disorder accompanied by enteritis. The bifidobacterium longum NSP001 is used for preparing a pharmaceutical composition and fermented food for relieving ulcerative colitis, and has a very wide application prospect.

The invention relates to the technical field of medicines, in particular to an application of a bromodomain protein 4 (BRD4) inhibitor JQ1 or a derivative thereof in preparation of a medicine for treating sepsis intestinal barrier injury. Experiments show that in a lipopolysaccharide (LPS)-induced sepsis mouse intestinal barrier injury model, the BRD4 inhibitor JQ1 can effectively inhibit LPS-induced sepsis mouse intestinal mucosa damage, release of inflammatory factors TNF[alpha], IL1[beta] and IL18, release of NLRP3 complex inflammasome, and high expression of pyroptosis marker genes GSDMD,GSDME, P2X7 and Aim2. Results show that the BRD4 inhibitor JQ1 can effectively prevent the sepsis mouse intestinal barrier injury by inhibiting intestinal tissue cell pyroptosis, and can be used for preparing a pharmaceutical preparation for treating the sepsis intestinal barrier injury.

The invention discloses application of 2'-fucosyllactose to regulation of host intestinal flora and enhancement of intestinal barriers, and belongs to the technical field of biological medicine. The new application includes an application of the 2'-fucosyllactose to preparation of drugs for regulating the host intestinal flora and enhancing the intestinal barriers, an application of the 2'-fucosyllactose to preparation of health food for regulating the host intestinal flora and enhancing the intestinal barrier, and an application of the 2'-fucosyllactose to preparation of food for regulating the host intestinal flora and enhancing the intestinal barriers. The situation that the 2'-fucosyllactose has effects in regulating the host intestinal flora and enhancing the intestinal barriers, andcan be used for preventing and relieving intestinal flora disorder and intestinal barrier damage caused by pathogenic bacteria infection and the like is disclosed for the first time.

The invention relates to the field of fermentation engineering, in particular to a ganoderma lucidum sporocarp microbial fermentation preparation for treating intestinal flora disorder and intestinalbarrier function impairment. A ganoderma lucidum sporocarp extract and probiotic strains are fermented together to obtain a fermented product, ganoderma lucidum sporocarp powder is prepared into a ganoderma lucidum extract with the concentration of 5-35 mg / ml, and then the ganoderma lucidum extract with the concentration of 5-35 mg / ml is added into an MRS culture medium with the sugar content of 0.1-1%. Preferably, the inoculated probiotics are bacillus subtilis, bacillus subtilis strains are inoculated into the MRS culture medium containing the ganoderma lucidum extract at the concentration of 1%, anaerobic culture is conducted for 48 h in the environment of 37 DEG C after inoculation, fermentation is conducted, and a fermentation product is obtained, so that damage, caused by flora disturbance, to the intestinal barrier function can be relieved.

The present invention relates to administration of sweet whey protein (SWP) for promoting the enteric neuronal development in infants, especially preterm, low birth, very low and extremely low birth weight infants as well as in young children up until the age of six. Administration of the SWP according to the invention prevents and treats disorders associated with an immature or impaired enteric nervous system. The disorders are, notably, dysfunctional gastrointestinal motility manifested as slow intestinal transit, intestinal discomfort, hard stools, constipation and / or gastrointestinal reflux, gut barrier dysfunction, food intolerance or necrotizing enterocolitis.

The invention discloses a plant extract additive for improving intestinal health of livestock and poultry, and belongs to the field of feed additives. Intestinal tracts are digestion and absorption places of livestock and poultry nutrient substances, intestinal tract damage certainly causes diarrhea, diarrhea and the like, the phenomena of low feed conversion rate, reduced growth performance and the like are caused. The plant extract additive comprises the following main components: 10-30 parts of a plant essential oil compound, 10-30 parts of plant polysaccharide, 10-20 parts of medium and short chain fatty acid and 50-70 parts of a carrier, wherein the plant essential oil compound is prepared by mixing one or more of cinnamyl aldehyde, thymol, carvacrol, eugenol and allicin according to a specific proportion; the plant polysaccharide is prepared by mixing one or more of astragalus polysaccharide, ganoderma lucidum polysaccharide and gingko polysaccharide according to a specific proportion; and the medium and short chain fatty acid is prepared by mixing one or more of caprylic acid, capric acid and lauric acid according to a specific proportion. Breeding test results show that the plant extract compound feed additive has the functions of obviously improving intestinal flora structures of the livestock and poultry, promoting intestinal villus development and the like besides remarkable anti-inflammation and sterilization effects. The feed additive has the characteristics of wide antibacterial spectrum, difficulty in generating drug resistance, no pollution to the environment and the like, can effectively kill harmful bacteria in intestinal tracts of livestock and poultry, also has the effects of promoting intestinal villus development, intestinal barrier repair and the like, improves the digestion and absorption of organisms on nutrient substances, enhances the disease resistance of flora and improves the breeding benefits of the livestock and poultry.

The invention provides a novel coronavirus intestinal infection model construction method based on a micro-fluidic organ chip, and particularly aims at simulating and constructing a series of intestinal tissue pathophysiological changes such as intestinal barrier integrity damage, mucus secretion abnormity and intestinal immune response activation occurring after novel coronavirus infection. The micro-fluidic chip is mainly composed of two layers of micro-channels, the channels are separated by a polydimethylsiloxane wedge-shaped porous membrane, each layer of channel is provided with an inlet and an outlet, and a static or dynamic environment can be formed through fluid. By respectively inoculating intestinal epithelial cells and endothelial cells into the upper channel and the lower channel on the chip and introducing circulating immune cells into the lower channel after virus infection, the miniature intestinal tissue on the chip is formed. Novel coronavirus particles are added into an upper channel of the chip, so that novel coronavirus exposure of intestinal tissues is simulated. The invention provides a multi-factor participated tissue level research system for the research of the SARS-CoV-2 infected intestinal pathogenesis.

A palatable, single serving dietary supplement of amino acids that may be taken as a nutritional aid to improve health and well-being by promoting higher quality sleep, enhancing repair of muscular tissue after strenuous exercise in part through boosting the natural production of human growth hormone, enhancing the immune system, improve gut barrier function, aiding in responses to upper respiratory viral pathogens, reversing side effects from the over use of nutritional energy drinks with stimulants and simple sugars and reverse the side effects of excess signaling through the cortisol pathway resulting from chronic environmental stress.

The present invention pertains to an in vitro method for detecting intestinal barrier failure in an avian population, the method comprising the following steps: a) collecting a pooled fecal sample deriving from an avian population and b) determining the amount of at least one protein marker contained in said sample; wherein the at least one protein marker comprises or consists of an acute phase protein or a functional fragment thereof, and wherein an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.

The invention discloses an application of decitabine in the preparation of a medicine for treating inflammatory bowel diseases. The decitabine can improve the proportion of spleen regulatory T cells of mice with inflammatory bowel diseases. The content of regulatory T cell related cytokines in colon tissues of mice with inflammatory bowel diseases can be increased; the expression of tight junctionprotein of colon tissues of mice with inflammatory bowel diseases can be improved; and colon lesions of inflammatory bowel diseases of mice can be obviously controlled. Decitabine can induce immune tolerance of inflammatory bowel disease patients to intestinal non-pathogenic antigens, recover intestinal barrier functions, improve effective rate and alleviation rate, and reduce recurrence rate.

The invention relates to an improvement of completeness of an intestinal barrier, in particular to a method for exciting the barrier completeness of mammalian by applying a composition containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA) and at least two different oligosaccharides to the mammalians.

The present invention relates, inter alia, to ghrelin analogs and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and / or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.

The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

The invention discloses application of rutin as a growth promoting agent in poultry feed. It is found for the first time that when 200-1500 mg / kg of rutin is added into a feed for white feather broilers, the immunity of the broilers can be effectively enhanced, the intestinal barrier function is improved, ingestion of the broilers is promoted, and the daily gain and the feed utilization efficiency are improved. The rutin disclosed by the invention has the advantages of being green, environment-friendly, wide in source, low in cost and the like, and is a safe and efficient green feed growth promoting additive.

The invention belongs to the technical field of nutrient supplementing of dietary foods, and particularly relates to new application of barley leaves. The new application has the advantages that the intestines diseases are treated and / or prevented by the barley leaves through inhibiting the colitis symptoms of the DSS (dextran sulphate sodium)-induced mouse, such as diarrhea and hematochezia; themicroenvironment of intestines is improved by regulating the composition of intestine flora, the proliferation of enterocytes and the increasing of intestinal mucus are promoted, and the intestine barrier function is improved; the obvious promotion function on the application of the barley leaves on market is realized, and a novel intestine dietary intervention path is favorably opened.